viewAchillion Pharmaceuticals, Inc.

Achillion crumbles as FDA keeps hold on Hepatitis C drug


Achillion Pharmaceuticals Inc. (NASDAQ:ACHN), a U.S. drug developer, lost half of its market value in early trading after regulators decided not to lift a clinical hold they had placed on the company’s experimental hepatitis C drug, sovaprevir, because of abnormal liver results.

Achillion shares tumbled 52 percent to $3.47 at 9:34 a.m. in New York, leaving the company with a market value of $338.25 million.

The U.S. Food and Drug Administration determined the compound’s development shouldn’t resume after the company responded to all the issues raised by the agency in June, the New Haven, Connecticut-based company said in a statement after markets closed on Sept. 27.

"While we are disappointed that we were not able to resolve the clinical hold at this time despite having addressed all the issues," Achillion's Chief Executive Milind Deshpande said in the statement, "we believe the breadth of our portfolio allows us to quickly advance other all-oral combination regimens for the treatment of HCV."

The company said it will focus on other hepatitis C drugs in its portfolio, with results of a planned combination study of two medications by next year.

Hepatitis C is a virus that can lead to life-threatening liver damage and is the main cause of liver transplants in the U.S.   Hepatitis C is estimated to affect 170 million people worldwide.

Achillion is competing with drugmakers including Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), AbbVie Inc. (NYSE:ABBV) and Gilead Sciences Inc. (NASDAQ:GILD), the world’s largest maker of HIV medicines, to develop new treatments for Hepatitis C.

Achillion shares were lowered by Piper Jaffray Cos. to “neutral” from “overweight” in a research note issued today. The stock was also downgraded at Bank of America Corp. to an "underperform" rating from a "neutral" rating. JMP Securities, in turn, lowered the shares to "market perform" from "outperform."

JPMorgan Chase & Co. downgraded the stock to a "neutral" rating from an "overweight" rating. JPMorgan also lowered its price target on the shares to $4.00 from $12.00.





Quick facts: Achillion Pharmaceuticals, Inc.

Price: - -

Market: NASDAQ
Market Cap: -

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



OptiBiotix Health secures significant exclusive licence agreement for OptiBiome

OptiBiotix Health PLC's (LON:OPTI) Stephen O'Hara chats to Proactive's Andrew Scott after signing an exclusive licence agreement for its OptiBiome weight loss ingredient with Australian firm OptiPharm Pty Ltd. OptiPharm owns Optislim, the number one weight management brand in Australia, which...

13 hours, 49 minutes ago

2 min read